University of Leicester
Browse

Assessment of an oral corticosteroid withdrawal pathway for severe asthma patients receiving biologic therapies

journal contribution
posted on 2025-04-16, 14:56 authored by Hnin Wint Wint AungHnin Wint Wint Aung, Richard J Russell, Claire E Boddy, Kumaran Balasundaram, Eleanor Hampson, Mark Bell, Lauren A Parnell, Michelle A Bonnington, Syed Mohammad, Miles Levy, Karim Meeran, Salman Siddiqui, Shamsa Naveed, Peter Bradding
<p dir="ltr">Background</p><p dir="ltr">The optimal approach for weaning maintenance oral corticosteroids (mOCS) in severe asthma patients receiving biologics remains unclear. Previous studies assessed hypothalamic-pituitary-adrenal function at 5 mg daily prednisolone, a supraphysiological dose for many, necessitating further mOCS reduction for adrenal recovery.</p><p dir="ltr">Objective</p><p dir="ltr">We evaluated a protocol-driven nurse-led mOCS withdrawal pathway with clinical oversight for severe asthma patients receiving biologics.</p><p dir="ltr">Methods</p><p dir="ltr">Severe asthma patients receiving biologics who had reduced mOCS to 5 mg prednisolone daily and maintained good asthma control, entered the withdrawal pathway. Prednisolone was decreased to 4 mg daily for 6 weeks then 3 mg daily for 6 weeks, followed by 09.00 serum cortisol measurement. Patients with cortisol >25 nmol/L followed a 20-week weaning protocol. Serum cortisol was re-checked 12 weeks after stopping mOCS.</p><p dir="ltr">Results</p><p dir="ltr">Of 102 patients, 92 had cortisol >25 nmol/L on 3 mg prednisolone and continued weaning. Seventy-three (72%) successfully discontinued mOCS with median [IQR] cortisol increasing from 192 [88-299] nmol/L on 3 mg prednisolone to 314 [248-437] nmol/L 12 weeks after discontinuation (p<0.0001). Twenty-nine patients (28%) paused weaning due to adrenal insufficiency symptoms (n=22), worse asthma control (n=1), anxiety (n=2) and other reasons (n=4). The baseline cortisol in this group was 53 [25-166] nmol/L, and they are currently well receiving median 3.0 [3.0-3.9] mg prednisolone. Duration of prior OCS use was significantly shorter in the successfully weaned group compared to those who failed (p=0.003). No serious adverse events occurred.</p><p dir="ltr">Conclusion</p><p dir="ltr">Most clinically stable asthma patients receiving biologics successfully withdrew mOCS without requiring dynamic adrenal function testing.</p>

History

Author affiliation

College of Life Sciences Respiratory Sciences

Version

  • AM (Accepted Manuscript)

Published in

The Journal of Allergy and Clinical Immunology: In Practice

Publisher

Elsevier BV

issn

2213-2198

Copyright date

2025

Available date

2025-04-16

Language

en

Deposited by

Dr Hnin Wint Wint Aung

Deposit date

2025-04-11

Usage metrics

    University of Leicester Publications

    Categories

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC